Our data show that docetaxel/trastuzumab combination caused a simultaneous hormone-receptor and HSP90 degradation and enhances the antitumour efficacy of docetaxel, suggesting that complete inactivation of AR could affect HID prostate cancers. The gene discussed is NR4A1; the disease is prostate carcinoma.